Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

• Mike Bastian,
• Nick Freemantle,
• Ana B. Rossi,
• Brad Shumel,
• Gaelle Bego Le Bagousse,
• Zhixiao Wang,
• Yingxin Xu,
• Patricia Guyot

Affiliations

Mike Bastian

Sanofi

Nick Freemantle

Institute for Clinical Trials and Methodology, UCL

Ana B. Rossi

Sanofi

Brad Shumel

Regeneron Pharmaceuticals Inc.

Gaelle Bego Le Bagousse

Sanofi

Zhixiao Wang

Regeneron Pharmaceuticals Inc.

Yingxin Xu

Regeneron Pharmaceuticals Inc.

Patricia Guyot

Sanofi